News
News
Press Release | Pregene be Listed as Shenzhen "professional, proficient, special, new" medium-sized and small enterprise in 2021
Latest news
browse:843
time:2021.06.15

On June 15, the Shenzhen Municipal Bureau of Industry and Information Technology announced the list of "professional, proficient, special, new" medium-sized and small enterprise in Shenzhen in 2021. Shenzhen Pregene Biopharma Co., Ltd (Pregene) get listed for its R&D ability of product and technologies of cell and gene therapy.


According to the Selection Methods for Specialized and Special New Small and Medium-sized Enterprises of Shenzhen Municipal Bureau of Industry and Information Technology (No. 12 [2020] of Shenzhen Municipal Bureau of Industry and Information Technology), the selection scope of "professional, proficient, special, new" medium-sized and small enterprise in 2021 focuses on strategic emerging industries, core basic components (components), key basic materials, advanced basic processes, industrial technology bases, as well as basic software and other fields of small and medium-sized enterprises.


Get listed as one of the "professional, proficient, special, new" medium-sized and small enterprises shows government’s recognition of the enterprise.


图片8.png


图片9.jpg


About Pregene

Shenzhen Pregene Biopharma Co., Ltd has renowned institutional investors as its shareholder, including National Small and Medium-sized Enterprise Development Fund, Guokegahe Fund under the Chinese Academy of Sciences, Shenzhen Capital Group, Haier Biomedical and Huapont Life Sciences. The company focuses on the R&D and promotion of cell and gene therapy drugs and participated in drafting the national drug standard "Key Points to Consider in the Quality Control Testing and Non-clinical Evaluation of CAR-T Cells" issued by the National Institutes for Food and Drug Control in June 2018. Pregene has completed a series of process development for multiple cutting-edge projects such as universal CAR-T, dual-target CAR-T, TCR-T, mRNA, and stem cells. Other product pipelines for cancer, autoimmune diseases and other indications have developed in steps, providing richer technology reserve and broader development prospect to the company.


636e300479081.jpg

Pregene R&D and Manufacturing Center in Shenzhen